The purpose of this study was to determine the effect of heparin-binding epidermal growth factor (HB-EGF) on human embryo development in vitro from days 2 to 14 post-insemination. Embryos were cultured in a complex serum-free medium (CSFM3) in the absence and presence of 1 nM and 100 nM HB-EGF. Development to the blastocyst stage of A-C-grade embryos (A grade ⍧ highest quality) was improved in the presence of 1 nM HB-EGF from 40.7% to 65.4% and significantly increased to 71.0% in the presence of 100 nM HB-EGF (P < 0.05). Moreover, the percentage of blastocysts hatching was improved in the presence of 1 nM HB-EGF from 45.5% to 70.5% and almost doubled to 81.8% (P < 0.05) in the presence of 100 nM HB-EGF. HB-EGF promoted the development of highgrade (classed as BG1) and medium-grade (BG2) blastocysts. There was no difference in blastocyst quality between the control and HB-EGF-treated embryos as assessed by blastocyst cell number and consumption of the major energy substrates, pyruvate and glucose, measured on day 6 of culture. Further development was assessed by culturing the blastocysts on growth factor-reduced Matrigel (GFRMatrigel). Adherence and outgrowth were observed, with these embryos producing significantly more human chorionic gonadotrophin over days 7-14 compared with those cultured on plastic (47.8 ⍨ 8.0 mU versus 23.0 ⍨ 8.6 mU). The addition of recombinant human growth factors to clinical in-vitro fertilization medium may be useful in promoting embryo development with a view to carrying out blastocyst transfers.
Introduction
A major focus of human embryo research is aimed at promoting blastocyst development in vitro, with a view to carrying out day-5 embryo transfers for in-vitro fertilization (IVF) (Ménézo et al., 1992; Kaufman et al., 1995; Olivennes et al., 1995) and for maximizing the potential of embryos donated for research. This can be achieved using co-culture, with either autologous cells (Bongso et al., 1992; Freeman et al., 1995; Quinn and Margalit, 1996) or established cell lines (Ménézo et al., 1990 (Ménézo et al., , 1992 . However, whilst co-culture has been shown to promote the development of human embryos in vitro, there are concerns about potential contamination and the practicality of using coculture routinely in IVF. Another approach has involved the manipulation of media constituents resulting in the generation of new media such as KSOM, modified SOM, derived from sequential simplex organisation methods Biggers, 1991a, 1991b) and modified human tubal fluid (Quinn, 1995; Quinn et al., 1995) , and in the development of sequential media, G1 and G2 (Barnes et al., 1995) .
The addition of recombinant growth factors to embryo culture medium has been shown to promote in-vitro blastocyst development in a number of species (Paria and Dey, 1990; Dardik and Schultz, 1991; Harvey and Kaye, 1992; Das et al., 1994; Dunglison et al., 1996; Palma et al., 1997) . Since mammalian embryos are exposed to growth factors in vivo, we have investigated the effect of adding human recombinant growth factors to a serum-free culture medium in an effort to promote the development of human embryos to the blastocyst stage and beyond. We have shown previously that addition of 1000 IU/ml leukaemia inhibitory factor (LIF) doubled blastocyst formation rates from 18.4% to 43.6%, although the embryos developed only as far as the expanded blastocyst stage (day 7) with none going on to hatch (Dunglison et al., 1996) . Studies using mammalian embryos in vitro have shown that other growth factors are essential for later pre-implantation development and that a prime candidate is heparin-binding epidermal growth factor (HB-EGF) (Das et al., 1994; Raab et al., 1996) .
HB-EGF exists both as an insoluble transmembrane form (HB-EGFtm) and a soluble paracrine form (HB-EGFsol), which is released by proteolytic cleavage of HB-EGFtm. The effects of HB-EGF are mediated through its binding to the epidermal growth factor receptor (EGF-R) and to immobilized heparin, in the form of cell-surface heparin sulphate proteoglycans (HSPG). Evidence in the mouse suggests an important role for both forms of HB-EGF, and its receptor EGF-R, during blastocyst development and implantation. HB-EGF mRNA is expressed in mouse uterine luminal epithelium only at the site of blastocyst apposition, approximately 6-7 h prior to adhesion (Das et al., 1994) . Furthermore, HB-EGF is not expressed in the pseudopregnant uterus, suggesting that the blastocyst provides the signal for its induction. The addition of HBEGFsol to culture medium has been shown to increase blastocyst cell numbers and promote hatching, as well as trophoblast outgrowth in vitro (Das et al., 1994) . The transmembrane form of HB-EGF may have a role in the adhesion of blastocysts to the endometrium (Raab et al., 1996) . Mouse blastocysts were shown to adhere preferentially to murine cells transfected with HB-EGFtm rather than those expressing HB-EGFsol or parental (Birdsall et al., 1996; Yoo et al., 1997) . During the proliferative phase of the menstrual cycle, HB-EGF mRNA expression is low, but levels increase during the secretory phase reaching a peak immediately prior to the implantation window (days 19-21), before decreasing again. During the proliferative phase, HB-EGF expression is confined to the stroma, but in the mid-secretory phase it is also present at the apical surface of the luminal epithelium (Yoo et al., 1997) . This pattern of HB-EGF expression suggests that it may play a role in preimplantation development, and hence we have studied the effects of HB-EGF on human embryos in vitro.
Materials and methods
All of the embryos were donated with informed consent by couples attending the Oxford Fertility Unit, John Radcliffe Hospital, Oxford. Ethics approval for the study was obtained from the Central Oxford Research Ethics Committee and the Human Fertilisation and Embryology Authority.
Ovarian stimulation
Details of ovarian stimulation, oocyte retrieval and embryo transfer at the Oxford Fertility Unit have been published previously (Dokras et al., 1990) . Briefly, ovarian stimulation is achieved by pituitary down-regulation with Nafarelin (Searle, High Wycombe, UK) starting on day 21 in the luteal phase of the cycle, followed by Metrodin (Serono, Welwyn Garden City, UK) administration for 9-13 days. The cycle is monitored biochemically, and follicular development is assessed using vaginal ultrasound. Oocyte retrieval is performed 35 h following human chorionic gonadotrophin (HCG) administration.
Embryo culture
Oocytes and embryos were initially cultured singly in 1 ml of T6 medium supplemented with 10% human serum albumin (HSA, Zenlab 4.5 solution, cat no. ADL10; Bio Products Laboratory, Elstree, UK), in a humidified atmosphere of 5% carbon dioxide in air at 37°C. On day 2 following insemination, normally fertilized embryos were graded, using the criteria described in Table I , and up to a maximum of three embryos were selected for transfer. Embryos surplus to treatment and freezing were then cultured in a complex serum-free medium (CSFM3) containing 2.5% HSA, in either the presence or absence of 1 nM or 100 nM HB-EGF. CSFM3 was based on the CSFM devised by Dunglison et al. (1996) , except for the addition of 20 ml/l of essential amino acids (50ϫ Eagle's minimum essential medium (13-606E), Bio Whittaker, Reading, UK) and a reduction in the concentration of both glucose and L-lactate to 0.11 mM and 1 mM, respectively. Table I summarizes the grading system used to assess embryo morphology on day 2 post-insemination. Only grade A-D embryos were included in the present study. Embryos developing to the blastocyst stage were graded according to Dokras et al. (1993) . Briefly, blastocysts forming on days 5 to 6, which exhibited an expanded cavity with a distinct trophectoderm (TE) and an eccentrically placed inner cell mass (ICM), were classed as BG1. BG2 blastocysts were those which were morphologically identical to BG1 embryos but developed 24-48 h later, on days 6 to 7. BG3 blastocysts developed on days 5 to 7, but exhibited poor morphology, characterized by a number a degenerative foci in the ICM and TE, and a poorly developed cavity. All of the grading was performed by the same person (K.L.M.).
Embryo classification and grading

Embryo allocation
It was considered important to ensure that the distribution of embryo grades was similar between each treatment group to be certain that no bias was given to any one of the categories (Table II) . Embryos from a single patient were evenly distributed at random between the three groups where possible, since the developmental potential of embryos from individual patients can differ significantly.
The effect of HB-EGF on human embryo development from day 2 to 7 post-insemination
The effect of HB-EGF on human embryo development was assessed by culturing embryos individually from day 2 to 7 in CSFM3 in the presence or absence of 1 nM or 100 nM HB-EGF (R & D Systems, Abingdon, Oxon, UK). The embryos were cultured in 100µl drops of medium overlaid with 1 ml paraffin oil (Boots Pharmaceuticals, Nottingham, UK) in a single well of a 24-well Nunclon plate (Nunc, Delta, Denmark). The number of embryos cleaving to each developmental stage was expressed as a percentage of the total number of embryos. Blastocyst quality on day 6 was assessed in a separate group of embryos by determination of: (i) the total cell number on day 6; and (ii) consumption of the major energy substrates, pyruvate and glucose, on day 6. Blastocyst cell numbers were determined in embryos cultured up to day 6 in 100 µl drops, as described previously. Following the removal of the zona pellucida with acid Tyrode's solution (pH 2.1; Nicolson et al., 1975) , the cell nuclei were labelled with the fluorochrome, bisbenzamide (Hoechst 33258; Sigma, Poole, Dorset, UK), and the embryo visualized under a fluorescence microscope (Handyside and Hunter, 1984) .
Metabolism measurements were determined in embryos cultured from day 2 in 4 µl drops, in a 35 mm culture dish overlaid with 3 ml of pre-equilibrated paraffin oil. Each individual embryo was transferred to a fresh drop every 24 h, and the spent drops were frozen at -70°C prior to analysis. An ultramicrofluorescence technique was used to measure the concentrations of pyruvate and glucose in the incubation droplets and control medium from day 6 (Martin and Leese, 1995) . Briefly, this method is a miniaturization of the conventional methods of enzymatic analysis whereby the nucleotides NADH and NADPH are generated or consumed in coupled reactions. As described by Martin and Leese (1995) , 1 µl of culture medium was added to 10 µl of reaction mixture under paraffin oil. The change in fluorescence due to the oxidation of NAD or NADP, or the reduction of NADH or NADPH, was monitored using a Leica DMRBE fluorescence microscope (Leica, Milton Keynes, UK) linked to a Photonics Science CCD camera. The intensity of fluorescence was analysed using Openlab 1.7 software (Improvision, Coventry, UK). Standards of known substrate concentration were included in each assay, enabling quantification of the change in fluorescence. The rate of nutrient uptake was calculated from the differences in substrate concentration between the control and incubation droplets and expressed in pmol/embryo/h.
The effect of HB-EGF on human embryo development from day 7 to 14 post-insemination
To investigate the effect of HB-EGF on development from day 7 to 14, embryos developing to the blastocyst stage were transferred on day 7 to either a fresh 100 µl drop of medium overlaid with paraffin oil or to a single well of a 24-well plate coated with 200 µl of growth factor-reduced Matrigel (GFR-Matrigel) (Becton Dickinson Labware, Oxford, UK) overlaid with 400 µl of fresh medium. All blastocysts were observed up to day 14. Medium from day 7 to 14 was collected and frozen at -20°C. The amount of intact HCG in culture medium was measured using a solid-phase, two-site fluoroimmunometric assay (Delfia HCG; Wallac, Milton Keynes, UK). The total amount of HCG (mU) produced by each embryo, cumulative over days 7-14, was calculated from the concentration of HCG measured in the medium (U/l) and the incubation volume (µl).
Statistical analysis
The proportion of embryos reaching each developmental stage in the control and HB-EGF-treated embryos was tested using Fisher's exact test. The levels of HCG produced by embryos cultured in the presence of HB-EGF were compared with those of the controls using Student's t-test.
Results
The effect of HB-EGF on human embryo development from day 2 to 7 post-insemination Figure 1 illustrates the percentage of embryos reaching each developmental stage in the three treatment groups: CSFM3 alone; CSFM3 ϩ 1 nM HB-EGF; and CSFM3 ϩ 100 nM HB-EGF. The growth of embryos to the morula, as well as the expanded and hatching blastocyst stages was improved in the presence of HB-EGF. The percentage of embryos developing to the blastocyst stage and the percentage of blastocysts hatching, in the three treatment groups, are shown in Table  III . The effect of embryo grade on blastocyst development was also scrutinized by dividing the embryos into two categories: A-C grades; and D grades alone. Development to the blastocyst stage of A-C-grade embryos was improved in the presence of 1 nM HB-EGF and significantly increased from 40.7% to 71.0% (P Ͻ 0.05) in the presence of 100 nM HB- Values are the meanϮSEM. *Significantly different from controls cultured in CSFM3 (P Ͻ 0.05). CSFM3 ϭ complex serum-free medium; HB-EGF ϭ heparin-binding epidermal growth factor.
EGF. Moreover, hatching was improved in 1 nM HB-EGFtreated embryos and was almost doubled from 45.5% to 81.8% (P Ͻ 0.05) in the presence of 100 nM HB-EGF. In contrast, the addition of HB-EGF to CSFM3 had no significant effect on the development of D-grade embryos to the blastocyst stage or on their hatching. The beneficial effect of HB-EGF was not to the detriment of blastocyst morphology assessed using the grading system of Dokras et al. (1993) . Moreover, the improvement in blastocyst development was seen as an increase in the number of embryos developing into the high-grade BG1 and BG2 blastocysts. The number of BG1 and BG2 blastocysts as a percentage of the total number of embryos (A-C grade) was improved from 37.0% for the control embryos cultured in CSFM3 alone, to 61.5% and 61.3% for the 1 nM and 100 nM HB-EGFtreated embryos, respectively. The percentage of poor-grade blastocysts (BG3) was similar in the three treatment groups: 3.7%, 3.8% and 9.6% for control, the 1 nM and 100 nM HB-EGF groups, respectively. The total cell number of embryos reaching the blastocyst stage cultured in the presence of 100 nM HB-EGF (95.0 Ϯ 8.0) was not significantly different from that of the controls (96.8 Ϯ 10.8; Figure 2 ). The rates of glucose and pyruvate consumption, the two major energy substrates utilized by the blastocyst, were also similar between the two treatment groups (Figure 3 ). Figure 4a illustrates a day-7 expanded, hatched blastocyst. All hatched blastocysts adhered to the GFR-Matrigel, irrespective of the presence or absence of HB-EGF (Figure 4b) . Following attachment to the GFR-Matrigel, the blastocyst cavity collapsed (Figure 4c ) and some exhibited trophoblast outgrowth of varying degrees (Figure 4d and e) . On average, the first signs of degeneration were observed on day 10. The addition of HB-EGF did not promote additional outgrowth compared with that of the controls. None of the hatched blastocysts adhered when cultured in the absence of GFR-Matrigel. Table IV shows the mean cumulative production of HCG by blastocysts in the three treatment groups cultured in the presence and absence of GFR-Matrigel. Whilst there was a tendency for hatching blastocysts to secrete more HCG than those which did not hatch, these differences were not significant, and the data have therefore been combined. HCG production by HB-EGF-treated embryos cultured in either the presence or absence of GFR-Matrigel was not significantly different from that of the controls. The mean cumulative HCG production of all embryos from the three treatment groups cultured in the presence of GFR-Matrigel was significantly greater than all those embryos grown in its absence.
The effect of HB-EGF on human embryo development 7-14 days post-insemination
Discussion
The addition of 100 nM HB-EGF to CSFM3 significantly improves the development of human embryos (A-C grade) to the expanded blastocyst stage and significantly promotes hatching. Moreover, the beneficial effect of HB-EGF promotes the development of high-grade BG1 and BG2 blastocysts. However, as well as assessing morphology, it is important to measure other parameters associated with embryo growth and quality in order to determine whether the development of HB-EGF-treated embryos is affected. The need for this was illustrated by experiments in which ovine embryos cultured in the presence of human serum gave rise to overweight lambs (Thompson et al., 1995) , demonstrating that culture conditions may in some cases be detrimental to pregnancy outcome. In this study, we have shown that the quality of blastocysts developing in the presence of HB-EGF is similar to that of blastocysts cultured in CSFM3 alone, assessed by measurement of blastocyst cell numbers and nutrient consumption on day 6, and the cumulative production of HCG from days 7-14.
Two parameters associated with embryo development for days 2-7 post-insemination were measured on day 6: total blastocyst cell numbers; and the uptake of the energy substrates pyruvate and glucose. The importance of measuring blastocyst cell numbers as an indicator of the rate of cell proliferation and as a criterion for assessing embryo development has been illustrated previously (Hardy et al., 1989a) . For example, the omission of glucose from mouse-embryo culture medium significantly reduces cell numbers but has little effect on development to the blastocyst stage (Martin and Leese, 1995) . The blastocyst cell numbers obtained in this study (96.8 Ϯ 10.8) compare favourably with those reported previously of 82.2 Ϯ 7.8 for human embryos cultured in T6 plus maternal serum (Hardy et al., 1989a) , 58.4 Ϯ 8.2 for those in Earle's balanced salt solution (EBSS) ϩ 10% HSA (Conaghan et al., 1993) and 42.1 Ϯ 17.9 for embryos cultured in EBSS ϩ 15% A5 (Vlad et al., 1996) . In comparison, blastocysts arising from co-culture of embryos with mammalian cells have been shown to have similar or higher cell numbers to those obtained in this study. Vlad et al. (1996) reported blastocyst cell numbers of 62.9 Ϯ 23 for embryos co-cultured with ampullary cells from the 4-cell stage, and 120.7 Ϯ 41.9 for those co-cultured from the 2-cell stage. Substrate uptake by individual embryos has also been used to assess mammalian embryo development (Renard et al., 1980; Gardner and Leese, 1987; Hardy et al., 1989b; Lane and Gardner, 1996) . Improved development following transfer was observed with bovine blastocysts which consumed more glucose (Renard et al., 1980) , and mouse embryos with higher glycolytic activity were more likely to implant following transfer to a non-pregnant recipient (Gardner and Leese, 1987; Lane and Gardner, 1996) . The rates of glucose and pyruvate consumption, the two major energy substrates utilized by the blastocyst, by the control and the HB-EGF-treated embryos were similar to data reported previously (Hardy et al., 1989b; Gott et al., 1990; Conaghan et al., 1993) .
Development from day 7 to 14 post-insemination was assessed by measurement of the cumulative production of HCG. Dokras et al. (1993) demonstrated that high-grade Figure 4 . Human embryos cultured in a complex serum-free medium (CSFM3) on growth factor-reduced Matrigel (GFR-Matrigel) in the presence and absence of heparin-binding epidermal growth factor (HB-EGF): (a) day-7 expanded, hatched blastocyst cultured in CSFM3 ϩ 100 nM HB-EGF; (b) day-7 expanded, hatched blastocyst adhered to GFR-Matrigel cultured in CSFM3; (c) day-8 hatched blastocyst collapsing after adhering to GFR-Matrigel, cultured in CSFM3 ϩ 100 nM HB-EGF; (d) outgrowth and spreading from a day-9 hatched blastocyst adhered to GFR-Matrigel cultured in CSFM 3 ϩ 100 nM HB-EGF; and (e) extensive spreading and outgrowth from a day-10 hatched blastocyst cultured on GFR-Matrigel in CSFM3. Bar ϭ 60 µm. 
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blastocysts exhibiting typical development, with an expanded cavity lined by a distinct TE and having an eccentrically placed ICM, produce significantly more HCG than those of low quality. Poor-grade embryos were those with a number of degenerative foci and a poorly developed cavity. The cumulative production of HCG from day 7 to 14 by the HB-EGFtreated embryos was not significantly different from that of the controls. Overall, measurement of the three parameters associated with embryo quality, which are cell numbers, energy substrate uptake and HCG production, suggests that the beneficial effect of HB-EGF on development is not to the detriment of blastocyst quality. The stimulatory effect of HB-EGF on human embryo development is apparent from the 8-cell stage. This coincides with the timing of expression of the receptor for HB-EGF, the EGF-R, which has been detected in human embryos from the 8-cell through to the blastocyst stage using the reverse transcriptase polymerase chain reaction (Chia et al., 1996) . Similarly, mouse embryos have been shown to express func-tional EGF-R throughout preimplantation development (Wiley et al., 1992) . Furthermore, evidence in the mouse suggests a paracrine role for maternally derived HB-EGF, since the embryo itself does not express HB-EGF mRNA (Das et al., 1994) . HB-EGF is expressed in the ampulla and isthmus regions of the mouse oviduct (Dalton et al., 1994) , as well as in the uterine luminal epithelium (Das et al., 1994) , suggesting it may be important throughout the early preimplantation stages of development, as well as those just prior to and during implantation. Similarly in the human, maternally derived HB-EGF is likely to be important since it has been shown that HB-EGF is expressed in uterine endometrium (Birdsall et al., 1996; Yoo et al., 1997) , as is epidermal growth factor (EGF) (Imai et al., 1995) .
In addition to HB-EGF, other growth factors have been shown to stimulate cavitation and/or hatching in mammalian embryos, including LIF (Dunglison et al., 1996) , insulin-like growth factor-1 (IGF-1) (Harvey and Kaye, 1992) , EGF (Dardik and Schultz, 1991) , platelet-derived growth factor (PDGF) (Thibodeaux et al., 1993) and transforming growth factor-alpha (TGF-α) (Paria et al., 1990) . Various growth factors have also been shown to stimulate, for example IGF-1 (Harvey and Kaye, 1992) , or to inhibit cell proliferation, for example tumour necrosis factor-alpha (TNF-α) (Pampfer et al., 1994) ; to cause a decrease in glucose incorporation (TNF-α; Pampfer et al., 1994) or an increase in [ 35 S]methionine uptake (TGF-α; Dardik et al., 1992) ; to reduce apoptosis (TGF-α; Brison and Schultz, 1997) ; and to modulate gene expression (TGF-α and TGF-β; Babalola and Schultz, 1995) . Culture in the presence of HB-EGF had no effect on cell proliferation or nutrient uptake on day 6. The mechanisms by which growth factors promote blastocoele expansion are not well understood. Hatching has been attributed to both an embryo-derived factor and the increase in size/pressure associated with blastocyst expansion. A uterine factor, although not essential, may also be involved (Gonzales and Bavister, 1995) . The beneficial effect of HB-EGF on hatching suggests that this growth factor may at least in part fulfil this role, possibly by stimulating the production of an embryo-derived factor involved in zona thinning, or by promoting blastocoele expansion. In contrast to HB-EGF, EGF does not appear to have a significant mitogenic effect on mouse embryo development (Wood and Kaye, 1989; Brice et al., 1993) , but it has been shown to stimulate cavitation and protein synthesis in the trophectoderm (Wood and Kaye, 1989) , suggesting that EGF may have a more important role in differentiation (Wiley et al., 1995) .
The beneficial effects of HB-EGF observed on the A-Cgrade embryos were not observed with the lowest D-grade embryos. This may be explained in a number of ways. Firstly, low-grade embryos have a higher incidence of genetic abnormalities (Edirisinghe et al., 1992; Pellestor et al., 1994; Munné et al., 1995; Almeida and Bolton, 1996) so that a high proportion of these are developmentally incompetent from the outset. Secondly, inadequate expression of the EGF-R as a result of poor morphology may account for the lack of response. Indeed, the reduction in EGF-R expression at the blastocyst stage, after further development in vitro, has been attributed to a reduction in embryo quality as a result of sub-optimal 1650 culture conditions (Chia et al., 1996) . These findings show that caution must be observed when analysing the results from lowest-grade embryos.
Although HB-EGFsol has been shown to promote the outgrowth of mouse trophoblast on laminin-coated plastic dishes, we did not observe any additional effect with human blastocysts cultured on GFR-Matrigel. These conflicting observations may be attributed to a species variation, differences in culture conditions or the nature of the extracellular matrix. Very little is known about the nutritional requirements or the preferred extracellular matrix of human embryos from day 7 to 14 in vitro, therefore the absence of an additional effect of HB-EGF on trophoblast migration in this study may simply be attributed to sub-optimal culture conditions. Alternatively, human trophoblast outgrowth maybe more dependent on HBEGFtm, especially as it is the transmembrane form of HB-EGF which is involved in the adhesion of the mouse blastocyst to the endometrium (Raab et al., 1996) . HB-EGF has been shown to promote the migration of other mammalian cell types, including vascular smooth muscle cells and human corneal epithelial cells (Wilson et al., 1994; Miyagawa et al., 1995) , as well as stimulating the adhesive activities of cancer cells by up-regulating the expression of integrins Sato et al., 1996) . Both blastocyst attachment and trophoblast invasion of the decidualized endometrium are known to involve integrins, which have been shown to be developmentally regulated at the time of implantation in the mouse. The human embryo has also been shown to express β1-integrin at the time of implantation (Turpeenniemi-Hujanen et al., 1992) and therefore HB-EGF may have a role in human trophoblast invasion by promoting integrin expression.
In summary, the development of human A-C-grade embryos to the hatching blastocyst stage was improved in the presence of 100 nM HB-EGF. This evidence, together with its temporal and spatial expression in human endometrium (Yoo et al., 1997) , suggests that this growth factor may play an important role in human preimplantation development and early implantation. Furthermore, the addition of growth factors to serumfree medium may be useful with a view to carrying out blastocyst transfers in clinical IVF. However, whilst we have shown that in improving development to the hatching blastocyst stage embryo quality is not compromised, further assessment may be necessary. Additional parameters may include studying the effects on apoptosis and gene expression. Finally, the use of HB-EGF and other growth factors may be suitable for maximizing the development of embryos donated for research.
